TerraSante
Commercial- Indications
- Soil health, Biofertility
Company intelligence / Profile preview
MustGrow has transitioned from R&D to commercialization. Its flagship biofertility product TerraSante™ has commenced manufacturing/sales with initial ramp-up expected through late 2024–2026. The company’s signature soil biopesticide TerraMG™, based on mustard-derived compounds, has regulatory approval as a fertilizer/pesticide in the US and Canada for certain crops/states; further registration/commercialization efforts are ongoing globally under partnership with Bayer. Over a hundred independent tests have validated safety/effectiveness of its core products.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MustGrow Biologics.